Phaseline

Companies › Uniquity One (UNI)

Uniquity One (UNI): clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Respiratory, Gastroenterology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Solrikitug
IL-4 receptor alpha inhibitor
IL4RPhase 2COPD; Eosinophilic Esophagitis (EoE)Feb 2027
Solriktug (NSI-8226)–Phase 2Asthma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06496607Solriktug (NSI-8226)Phase 2AsthmaRespiratoryJul 2026
NCT06496620SolrikitugPhase 2COPDRespiratoryFeb 2027
NCT06598462SolrikitugPhase 2Eosinophilic Esophagitis (EoE)GastroenterologyApr 2027

Targets

IL4R (1)

Companies with the same targets

Apogee Therapeutics Guangdong Hengrui Pharmaceutical Sanofi Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical

Companies built like this

Connect Biopharm Aqualung Therapeutics Shanghai Novamab Biopharmaceuticals PPD Development, LP Upstream Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.